Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued on Tuesday. The brokerage set a "hold" rating on the medical research company's stock.

Several other research firms have also commented on CTSO. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Friday, May 2nd. HC Wainwright reiterated a "neutral" rating and issued a $1.00 target price on shares of Cytosorbents in a report on Thursday, April 3rd.

Cytosorbents Stock Performance

NASDAQ CTSO traded up $0.07 on Tuesday, reaching $0.90. 162,973 shares of the stock were exchanged, compared to its average volume of 146,321. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The firm has a market capitalization of $56.35 million, a PE ratio of -2.50 and a beta of 1.17. The company's 50-day simple moving average is $1.00 and its two-hundred day simple moving average is $0.99. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. Analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its position in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after acquiring an additional 37,519 shares in the last quarter. Avenir Corp grew its position in Cytosorbents by 63.1% in the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock valued at $5,045,000 after acquiring an additional 1,950,972 shares in the last quarter. CM Management LLC grew its position in Cytosorbents by 36.3% in the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock valued at $954,000 after acquiring an additional 254,076 shares in the last quarter. Skylands Capital LLC grew its position in Cytosorbents by 7.9% in the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock valued at $3,003,000 after acquiring an additional 221,080 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC grew its position in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after buying an additional 43,900 shares in the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.